Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for weak or absent esophageal peristalsis
2024-516667-91-00Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of buspirone in Ineffective Esophageal Motility (IEM), achalasia and dysphagia (2 arms), sponsored by UZ Leuven. Primary endpoint: Change in distal contractile integral (DCI) for liquid bolus in supine position. Started Oct 2024; status: completed.
02
Drugs
buspirone
03
Conditions
Ineffective Esophageal Motility (IEM)achalasiadysphagia
Beyond the preview
Go deeper on 2024-516667-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516667-91-00.